Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA-mDesmo
- Development stage
- Preclinical
- Lead developer
- Paul Scherrer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DOTA-mDesmo is an experimental radiopharmaceutical diagnostic tracer designed for positron emission tomography (PET) imaging of tumors that overexpress Desmoglein 3 (DSG3). Desmoglein 3 is a calcium-binding transmembrane glycoprotein and a member of the cadherin family of cell adhesion molecules, which is significantly upregulated in various squamous cell carcinomas (SCC), including head and neck squamous cell carcinoma (HNSCC), lung SCC, and cervical SCC. The tracer consists of a specific DSG3-binding monomeric peptide (mDesmo), derived from the binding domain of autoantibodies associated with pemphigus vulgaris, conjugated to the macrocyclic chelator DOTA and labeled with the positron-emitting radioisotope Gallium-68. By binding with high affinity to the extracellular domain of DSG3, 68Ga-DOTA-mDesmo enables the sensitive and specific localization of primary tumors and metastatic lesions, potentially improving the staging and monitoring of DSG3-positive malignancies.
- Other names
- [68Ga]Ga-DOTA-mDesmo68Ga-labeled monomeric desmoglein-targeting peptide
02
Targets
AVPR1B (Vasopressin V1b Receptor)DSG3 (Desmoglein-3)
Beyond the preview
Go deeper on 68Ga-DOTA-mDesmo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTA-mDesmo.